Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




DNA Health Monitoring Campaign Launched

By LabMedica International staff writers
Posted on 11 Feb 2014
A DNA health test aims to assist in prevention of diseases associated with DNA damage and poor DNA repair.

The Berkeley-based startup, Exogen Biotechnology (CA, USA), has launched a unique citizen science campaign on Indiegogo, a global “crowd funding” website (San Francisco, CA, USA). More...
The campaign is based on a laboratory test, which measures DNA breaks, the most lethal type of DNA damage and a potentially key indicator for overall health conditions. Launched on January 25, 2013, the project raised USD 20,000 in “crowd funding” within its first three days.

The technology measures physical breaks in the DNA of cells, which commonly result from an individual's lifestyle, environmental toxins, or personal genetics. The startup from the Lawrence Berkeley National Laboratory envisions that its DNA health monitoring technology will one day be as commonplace as a cholesterol test. The DNA health test aims to assist in prevention of diseases associated with DNA damage and poor DNA repair.

Exogen is allowing the public to assist in funding its large-scale citizen scientist project as well as gain access to the technology that is not yet available to the public. Supporters receive a kit that allows funders to safely collect three blood samples via sterile finger pricks. Blood samples are then mailed to Exogen’s proprietary research lab and analyzed either as a one-time event or on a regular basis throughout the year. The blood is processed for DNA damage and the results are made available back to the funder, securely and privately via a protected web application.

The core team behind the project is comprised of Dr. Sylvain Costes and Dr. Jonathan Tang, who are experts in understanding the link between ionizing radiation, DNA damage, and cancer induction. They developed this leading-edge technology over the past 10 years at the Lawrence Berkeley National Laboratory.

Dr. Tang commented, “Breaks in our DNA occur frequently, and our bodies repair them every day. However, as we age, the efficiency of how our bodies repair DNA breaks seems to weaken. This decline in repair efficiency can lead to accumulation of unrepaired DNA or misrepaired DNA, which may result in unpredictable and potentially lethal genetic mutations. Exogen hopes that monitoring DNA for breaks will allow individuals to assess the impact of various lifestyles and environments on their overall health and aging.”

Related Links:

Exogen Biotechnology



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.